Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
Steven F. Powell, MD
Advertisement
Articles by Steven F. Powell, MD
Advertisement
Latest Updated Articles
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited TissuePublished: October 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
2
The Essential Role of Clinical Social Work in Oncology
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
5
